However, CRISPR-Cas9-mediated inactivation of RIF1 did not reduce PARPi sensitivity in cultured KB2P tumor cells, suggesting that RIF1 loss might only drive resistance in vivo or that it is a consequence of PARPi treatment rather than causal to resistance (Figures S2F and S2G). The gene discussed is RIF1; the disease is neoplasm.